hVIVO (LON:HVO) Insider Sells £181,530 in Stock
by Tristan Rich · The Markets DailyhVIVO plc (LON:HVO – Get Free Report) insider Brendan Buckley sold 2,017,000 shares of the stock in a transaction dated Friday, April 24th. The shares were sold at an average price of GBX 9, for a total transaction of £181,530.
hVIVO Trading Up 2.0%
hVIVO stock traded up GBX 0.15 during trading hours on Friday, hitting GBX 7.75. The company had a trading volume of 8,278,495 shares, compared to its average volume of 3,706,620. The firm has a market cap of £53.35 million, a P/E ratio of 10.06 and a beta of 1.67. The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63. hVIVO plc has a 1 year low of GBX 4.31 and a 1 year high of GBX 19.50. The company has a 50-day moving average price of GBX 7.91 and a two-hundred day moving average price of GBX 6.88.
hVIVO (LON:HVO – Get Free Report) last released its quarterly earnings data on Wednesday, April 15th. The company reported GBX (0.87) earnings per share (EPS) for the quarter. The company had revenue of GBX 4,677 million during the quarter. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%. On average, sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.
Wall Street Analyst Weigh In
HVO has been the subject of several research reports. Stifel Nicolaus reissued a “hold” rating and issued a GBX 10 price objective on shares of hVIVO in a research report on Wednesday, April 15th. Shore Capital Group reissued a “buy” rating on shares of hVIVO in a research report on Wednesday. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of GBX 15.
View Our Latest Stock Analysis on HVO
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.